Imugene Limited

About Imugene Limited

Imugene Limited is a clinical stage immuno-oncology company focused on developing new treatments to activate the immune system of cancer patients to identify and eradicate tumors. Their vision is to transform and improve cancer treatment and the lives of patients through innovative therapies supported by clinical evidence and peer-reviewed research.

Products & Services

Allo CAR T Cell Therapy (azer-cel):An off-the-shelf allogeneic CAR T drug targeting CD19 to treat blood cancers, currently in Phase 1b trial for diffuse large B cell lymphoma (DLBCL) patients who relapsed off autologous CAR T therapy.

onCARlytics (CF33-CD19):A combination immunotherapy using the CF33 oncolytic virus to deliver and present CD19 antigen on cancer cell surfaces, promoting CD19 CAR T cell anti-tumor responses against solid tumors.

CF33 Oncolytic Virus (VAXINA):A potent oncolytic virus developed from multiple vaccinia virus strains, featuring the hNIS gene for in vivo imaging, aimed at treating various cancers.

B-Cell Immunotherapies:Cancer vaccines that induce the body to produce antibodies against validated oncology targets like HER2 (HER-Vaxx) and PD-1 (PD1-Vaxx).

Specialties

Immuno-Oncology CAR T Cell Therapy Oncolytic Virotherapy B-Cell Immunotherapies Cancer Treatment Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Options Issuance T: - FT: Options Issuance	A: 5501568 MR: - FA: 5,501,568 quoted options FAN: 5501568	D: 2025-09-01 FD: 2025-09-01	-

Options Issuance Latest

2025-09-01

$5.5M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Prasad S. Adusumilli

Deputy Chief, Thoracic Service; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; MD FACS FCCP

R

Rebecca Auer

Surgeon-Scientist

Y

Yuman Fong, MD

Chair of the Department of Surgery at City of Hope

P

Peter Schmid

Chair of Cancer Medicine

J

Josep Tabernero

President of ESMO

B

Bradley Glover

Chief Operating Officer

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Imugene Limited Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised